Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Collaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA SJP-0035 as an eye drop has been shown in prior Phase 1 and Phase 2 studies to be well tolerated at multiple doses tested in over 250 subjects. A planned Phase 2b trial would evaluate SJP-0035 administered in the Optejet dispenser. About Senju Pharmaceutical Co., Ltd. Senju is a privately held, research-based Japanese pharmaceutical company th ...